LLY241004P490000
- 0.52
- 0.000.00%
Eli Lilly and Co Newsroom
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly (NYSE:LLY) Eyes Broader Market for Weight-Loss Drugs
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Express News | Eli Lilly and Co - Medicine Foundry Expected to Add 400 Full-Time Jobs
Express News | Eli Lilly and Co - Facility to Open in Late 2027, Increasing U.S. Capital Commitment to $23 Billion
Eli Lilly to Build $4.5 Billion Research and Manufacturing Center to Propel Drug Pipeline
Lilly Announces New $4.5 Billion Site - the Lilly Medicine Foundry - to Drive Innovation in Drug Production and Make Medicines for Clinical Trials
US stock market outlook | Three major equity index futures all fell, 'mini non-farm' to be announced tonight.
On October 2nd (Wednesday) pre-market trading, the three major equity index futures of the US stock market all fell.
In September, influenced by the Federal Reserve's interest rate cut and optimistic sentiment about ai, the value of the technology market soared.
Fed rate cuts typically boost future profits and cash flow of high-growth companies. Buoyed by this, the market cap of many technology companies skyrocketed in September, with the continued enthusiasm for ai further driving the market cap growth. Tesla's market cap surged by 22.2% last month, reaching $834.4 billion by the end of September, mainly due to record electric autos sales in China in August, and Tesla's plans to roll out its Full Self-Driving (FSD) advanced driver-assistance software in China and Europe. Oracle's market cap climbed by 21.3% at the end of last month, reaching $472.2 billion.
Eli Lilly and Co (LLY.US) explores new uses for "miracle weight-loss drug" Zepbound, aiming to reduce the incidence of diabetes and other high-risk populations.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Sector Update: Health Care Stocks Retreat Tuesday Afternoon
Port Strike Fallout: Blockbuster Weight-loss Drug Supply From Wegovy to Ozempic, Mounjaro, Zepbound Caught up in East Coast Trade Shutdown
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points